



ATTORNEY DOCKET NO. 44481-5019-03

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Vanitha RAMAKRISHNAN *et al.*

Application No. 09/003,810

Filed: January 7, 1998

For: IMMUNOGLOBULIN POLYPEPTIDES  
TO HUMAN PDGF BETA RECEPTOR

Group Art Unit: 1644

Examiner: P. Gambel

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of the first Office Action on the Merits for the above-referenced application.

The present application is a continuation of parent Application No. 08/258,283, filed on June 10, 1994, (now U.S. Patent No. 5,817,310) which is a continuation-in-part of Application No. 08/253,440, filed June 7, 1994 (now abandoned) which is a continuation of Application No. 07/801,795, filed December 2, 1991 (now abandoned). The documents listed on the accompanying Form were previously cited in the copending parent applications. Thus, under 37 C.F.R. § 1.98(d), copies of the listed documents are not required to be provided.

Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

#9

RECEIVED  
PATENT CENTER  
OCT-7 AM 8:10  
1600/2300



This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

**Except** for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully submitted,  
**MORGAN, LEWIS & BOCKIUS LLP**

*Michael S. Tuscan*

Michael S. Tuscan  
Registration No. 43,210

October 5, 1999  
Customer No. 009629  
MORGAN, LEWIS & BOCKIUS LLP  
1800 M Street, NW  
Washington, D.C. 20036  
(202) 467-7000

RECEIVED  
TECH CENTER 1600/2900  
99 OCT - 7 AM 8:10